Skip to content

US · RLYB · BIOTECHNOLOGY

Rallybio Corporation (RLYB) intrinsic value and stock valuation

$15.47as of 2026-11-21 · Mkt cap 85.65M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Rallybio Corporation DCF and intrinsic value

InvestorsCraft values RLYB with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from RLYB’s statements →

Rallybio Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New Haven, CT 06510 rallybio.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$860K
20192025
Net income
-$-8.98M
20192025
Free cash flow
-$-29.81M
20192025
Total equity
$58M-15.7% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$860K$640K$0.00$0.00$0.00
Operating income-$-28.06M-$-60.5M-$-78.93M-$-67.88M-$-45.65M
Net income-$-8.98M-$-57.77M-$-74.56M-$-66.65M-$-47.01M
EPSd-$-1.6M-$-10.62M-$-14.74M-$-16.75M-$-11.69M
Operating cash flow-$-29.81M-$-49.28M-$-60.27M-$-57.28M-$-45.53M
Capital expenditure$0.00$0.00-$-10K-$-50K-$-330K
Free cash flow-$-29.81M-$-49.28M-$-60.28M-$-57.34M-$-45.87M
Total assets$62.3M$68.1M$115.6M$180.4M$182.2M
Total debt$180K$150K$390K$560K$0.00
Net debt-$-31.2M-$-13.75M-$-24.1M-$-56.4M-$-175.33M
Total equity$58M$61.7M$106.2M$169.3M$175.6M
Cash and short-term investments$54.7M$65.5M$109.9M$169M$175.3M
Income statement
20252024202320222021
Revenue$860K$640K$0.00$0.00$0.00
Cost of revenue$90K$130K$150K$170K$110K
Gross profit$770K$640K-$-150K-$-170K-$-110K
Research and development expenses$19.6M$41.5M$53.5M$40.7M$26.9M
Selling, general and administrative expenses$14.3M$19.6M$25.4M$27.2M$18.7M
Other expenses-$-5.09M$0.00$0.00$0.00$0.00
Operating expenses$28.8M$61.1M$78.9M$67.9M$45.7M
Cost and expenses$28.9M$61.1M$78.9M$67.9M$45.7M
Interest income$2.19M$4.22M$6.15M$1.96M$50K
Interest expense$0.00$0.00$0.00$0.00$10K
Depreciation and amortization$90K$130K$150K$170K$110K
Ebitda-$-27.97M-$-60.37M-$-78.78M-$-67.72M-$-45.39M
Operating income-$-28.06M-$-60.5M-$-78.93M-$-67.88M-$-45.65M
Total other income/expenses, net$19.1M$2.72M$4.37M$1.23M-$-1.36M
Income before tax-$-8.98M-$-57.77M-$-74.56M-$-67.73M-$-47.01M
Income tax expense$0.00$0.00$0.00-$-1.07M$0.00
Net income-$-8.98M-$-57.77M-$-74.56M-$-66.65M-$-47.01M
Weighted average shares outstanding$5.63M$5.44M$5.06M$3.98M$4.02M
Weighted average diluted shares outstanding$5.63M$5.44M$5.06M$3.98M$4.02M
Balance sheet
20252024202320222021
Cash and short-term investments$54.7M$65.5M$109.9M$169M$175.3M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$61.3M$67.8M$114.8M$179.5M$180.9M
Property, plant and equipment, net$200K$270K$590K$910K$510K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$240K$30K$810K
Total non-current assets$1.01M$270K$830K$940K$1.32M
Total assets$62.3M$68.1M$115.6M$180.4M$182.2M
Accounts payable$130K$280K$980K$1.11M$600K
Short-term debt$90K$150K$220K$180K$0.00
Deferred revenue$210K$850K$0.00$0.00$0.00
Total current liabilities$4.22M$6.24M$9.26M$10.7M$6.55M
Long-term debt$80K$0.00$170K$750K$0.00
Deferred revenue, non-current$0.00$210K$0.00$0.00$0.00
Total non-current liabilities$80K$210K$170K$370K$30K
Capital lease obligations$180K$150K$390K$560K$0.00
Total liabilities$4.3M$6.45M$9.44M$11.1M$6.58M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-302M-$-293.02M-$-235.25M-$-160.68M-$-94.03M
Accumulated other comprehensive income (loss)$20K$70K$10K-$-210K$0.00
Total equity$58M$61.7M$106.2M$169.3M$175.6M
Total investments$23.4M$51.6M$85.7M$112.1M$810K
Total debt$180K$150K$390K$560K$0.00
Net debt-$-31.2M-$-13.75M-$-24.1M-$-56.4M-$-175.33M
Cash flow statement
20252024202320222021
Net income-$-8.98M-$-57.77M-$-74.56M-$-66.65M-$-47.01M
Depreciation and amortization$90K$130K$150K$170K$110K
Stock-based compensation$5.31M$7.99M$10.9M$9.5M$3.65M
Change in working capital-$-4.19M-$-260K$4.28M-$-940K-$-3.78M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-150K-$-700K-$-100K$490K-$-980K
Net cash provided by operating activities-$-29.81M-$-49.28M-$-60.27M-$-57.28M-$-45.53M
Investments in property, plant and equipment$0.00$0.00-$-10K-$-50K-$-330K
Acquisitions, net$0.00-$-2M-$-2.25M-$-300K-$-2M
Net cash used for investing activities$47.3M$33.5M$27.7M-$-112.17M-$-2.33M
Common stock issued$20K$5.41M$140K$51.5M$86.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$20K$5.2M$140K$51.1M$83M
Net change in cash$17.5M-$-10.59M-$-32.46M-$-118.38M$35.1M
Cash at end of period$31.4M$13.9M$24.5M$57M$175.3M
Operating cash flow-$-29.81M-$-49.28M-$-60.27M-$-57.28M-$-45.53M
Capital expenditure$0.00$0.00-$-10K-$-50K-$-330K
Free cash flow-$-29.81M-$-49.28M-$-60.28M-$-57.34M-$-45.87M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Rallybio Corporation

        Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.

        CEO
        Stephen Uden
        Employees
        9
        Beta
        -0.89

        Explore

        Frequently asked questions

        What is the intrinsic value of Rallybio Corporation (RLYB)?

        Rallybio Corporation (RLYB) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is RLYB undervalued?

        RLYB trades at a price of $15.47 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.